Your browser is no longer supported. Please, upgrade your browser.
Settings
HALO Halozyme Therapeutics, Inc. daily Stock Chart
HALO [NASD]
Halozyme Therapeutics, Inc.
Index- P/E56.60 EPS (ttm)0.27 Insider Own5.20% Shs Outstand145.32M Perf Week0.33%
Market Cap2.20B Forward P/E- EPS next Y-0.70 Insider Trans-31.71% Shs Float128.95M Perf Month-2.00%
Income45.70M PEG1.03 EPS next Q-0.06 Inst Own89.30% Short Float4.10% Perf Quarter-11.49%
Sales281.20M P/S7.84 EPS this Y156.20% Inst Trans0.61% Short Ratio6.03 Perf Half Y-20.24%
Book/sh1.67 P/B9.08 EPS next Y-16.70% ROA9.40% Target Price21.33 Perf Year-27.07%
Cash/sh2.51 P/C6.05 EPS next 5Y55.00% ROE18.90% 52W Range14.33 - 21.48 Perf YTD-25.12%
Dividend- P/FCF24.28 EPS past 5Y24.10% ROI20.10% 52W High-29.38% Beta1.82
Dividend %- Quick Ratio3.00 Sales past 5Y49.50% Gross Margin95.70% 52W Low5.86% ATR0.78
Employees255 Current Ratio3.10 Sales Q/Q-59.80% Oper. Margin20.20% RSI (14)42.17 Volatility3.90% 4.95%
OptionableYes Debt/Eq0.61 EPS Q/Q- Profit Margin16.20% Rel Volume0.66 Prev Close15.25
ShortableYes LT Debt/Eq0.24 EarningsNov 06 AMC Payout0.00% Avg Volume877.02K Price15.17
Recom2.60 SMA20-4.06% SMA50-6.41% SMA200-15.37% Volume577,876 Change-0.52%
Oct-19-18Resumed Piper Jaffray Neutral
May-11-18Downgrade Barclays Equal Weight → Underweight $19
Jan-24-18Initiated Goldman Neutral
Oct-16-17Reiterated Piper Jaffray Overweight $26 → $29
Jan-06-17Downgrade Citigroup Buy → Neutral
Nov-03-16Initiated Deutsche Bank Buy $12
Dec-04-15Initiated Wells Fargo Outperform
Nov-18-15Initiated Citigroup Buy
Sep-22-15Initiated Barclays Overweight $27
Jun-22-15Reiterated JP Morgan Overweight $20 → $25
Mar-03-15Reiterated UBS Buy $16 → $21
Feb-18-15Reiterated MLV & Co Buy $15 → $20
Jan-08-15Reiterated MLV & Co Buy $12 → $15
Dec-24-14Initiated MLV & Co Buy $12
Jun-12-14Upgrade UBS Neutral → Buy $14 → $16
Jan-10-14Reiterated Barclays Equal Weight $12 → $15
Nov-11-13Reiterated UBS Neutral $8 → $14
Nov-11-13Reiterated Barclays Equal Weight $8 → $12
Aug-02-13Downgrade Barclays Overweight → Equal Weight $9 → $8
May-01-13Reiterated UBS Neutral $8 → $6.50
Dec-14-18 10:34PM  Hedge Funds Are Betting On Halozyme Therapeutics, Inc. (HALO) Insider Monkey
Dec-12-18 08:00AM  Halo Labs Announces Strategic Partnership in Lesotho Africa Business Wire
Dec-05-18 09:38AM  Halo Labs Announces Start of Production in California Business Wire
Dec-04-18 09:36AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Halozyme Therapeutics, Inc. (HALO) ACCESSWIRE -7.12%
Dec-03-18 05:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Halozyme Therapeutics, Inc. HALO GlobeNewswire
Nov-29-18 04:16PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Halozyme Therapeutics, Inc. - HALO PR Newswire
02:33PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Halozyme Therapeutics, Inc. (HALO) GlobeNewswire
10:43AM  What You Must Know About Halozyme Therapeutics Incs (NASDAQ:HALO) Financial Strength Simply Wall St.
Nov-27-18 07:32AM  The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial Benzinga -7.42%
06:55AM  Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Loxo Oncology ACCESSWIRE
Nov-26-18 04:05PM  Halozyme Announces Change In Primary Endpoint For HALO-301 To Overall Survival PR Newswire
Nov-19-18 05:00AM  Edited Transcript of HALO earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-16-18 07:00AM  Today's Research Reports on Trending Tickers: Loxo Oncology and Halozyme Therapeutics ACCESSWIRE
Nov-14-18 06:10AM  Halozyme Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Nov-09-18 08:00AM  Halo Labs Announces Dispensary Sales for the Month of October Business Wire
Nov-08-18 07:40AM  Report: Exploring Fundamental Drivers Behind Entergy, BLACKLINE INC, HollyFrontier, Hill-Rom, Apache, and Halozyme Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-06-18 07:05PM  Halozyme Therapeutics (HALO) Reports Q3 Loss, Misses Revenue Estimates Zacks
06:02PM  Halozyme Therapeutics: 3Q Earnings Snapshot Associated Press
04:05PM  Halozyme Reports Third Quarter 2018 Financial Results PR Newswire
09:23AM  A Preview Of Halozyme Therapeutics Q3 Earnings Benzinga
08:00AM  Halozyme Names Albert Kildani As Vice President Investor Relations And Corporate Communications PR Newswire
Nov-01-18 08:00AM  Halo Labs Announces Launch of Edibles in Oregon Business Wire +5.09%
Oct-30-18 08:00AM  Halozyme Licenses New ENHANZE® Targets For $25 Million Upfront Payment, Future Milestones And Royalties PR Newswire
Oct-26-18 08:00AM  Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Exelixis ACCESSWIRE
Oct-25-18 08:00AM  Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology PR Newswire +6.07%
Oct-23-18 10:38AM  Halo Labs Inc. Opens NEO Business Wire
Oct-22-18 08:00AM  Halozyme Provides Summary Results Of Data For PEGPH20 Combination Treatments Presented At ESMO 2018 Congress PR Newswire
Oct-17-18 11:06AM  Halo Labs Signs US$2 Million Per Month Extraction Agreement with Falcon International to Supply Cannabis Oil in California Business Wire
09:00AM  Market Trends Toward New Normal in Halozyme Therapeutics, Fitbit, Iconix Brand Group, Leap Therapeutics, LightPath Technologies, and Capricor Therapeutics Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Oct-15-18 10:41AM  Does Halozyme Therapeutics Incs (NASDAQ:HALO) PE Ratio Signal A Selling Opportunity? Simply Wall St.
Oct-10-18 04:05PM  Halozyme To Host Third Quarter 2018 Financial Results Conference Call PR Newswire
08:00AM  Halo Labs Launches 3 Brands in Nevada and Provides Update on Nevada Operations Business Wire
Oct-04-18 09:00AM  Halozyme Publication In The Journal Clinical Cancer Research Highlights New Nonclinical Data Supporting Multiple Effects Of PEGPH20 On The Tumor Microenvironment PR Newswire
Oct-03-18 09:30AM  Halo Labs Launches On NEO Business Wire
Oct-01-18 10:44AM  Halo Labs Announces Closing of Business Combination Stock to Commence Trading on October 3rd (NEO:HALO) Business Wire
Sep-20-18 04:15PM  Halozyme Therapeutics To Participate In Upcoming Investor Conference PR Newswire
Sep-17-18 08:00AM  Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin®) In Canada PR Newswire
Sep-10-18 08:00AM  Halozyme Appoints Bernadette Connaughton To Board Of Directors PR Newswire
Sep-07-18 11:27AM  Should You Worry About The Halozyme Therapeutics Incs (NASDAQ:HALO) Shareholder Register? Simply Wall St.
Sep-05-18 08:00AM  Halozyme Names Benjamin Hickey As Chief Commercial Officer PR Newswire
Aug-24-18 08:00AM  Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Akorn ACCESSWIRE
Aug-23-18 10:30AM  Recent Analysis Shows KB Home, Sleep Number, Exelixis, Sprint, PayPal, and Halozyme Therapeutics Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-22-18 08:30AM  Halozyme Therapeutics To Participate In Upcoming Investor Conferences PR Newswire
Aug-19-18 11:45PM  Edited Transcript of HALO earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-18 07:30AM  Halozyme Therapeutics (HALO) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:05AM  Halozyme Therapeutics: 2Q Earnings Snapshot Associated Press
Aug-07-18 04:21PM  Halozyme Reports Second Quarter 2018 Results PR Newswire
02:30PM  Halozyme Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 08:00AM  Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Repligen ACCESSWIRE
Jul-26-18 04:15PM  Halozyme Therapeutics To Participate In Upcoming Healthcare Conference PR Newswire
08:00AM  Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE® Technology PR Newswire
Jul-11-18 08:30AM  FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin PR Newswire
Jul-06-18 08:00AM  Halozyme To Host Second Quarter 2018 Financial Results Conference Call PR Newswire
Jun-26-18 03:38PM  How Did Halozyme Therapeutics Incs (NASDAQ:HALO) 25.81% ROE Fare Against The Industry? Simply Wall St.
Jun-22-18 07:30AM  Free Technical Research on ImmunoGen and Three More Biotech Equities ACCESSWIRE
Jun-13-18 08:00AM  Report: Exploring Fundamental Drivers Behind Virtu Financial, Littelfuse, Gogo, Brookfield Asset Management, Protalix BioTherapeutics, and Halozyme Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jun-11-18 08:30AM  Halozyme President And Chief Executive Officer, Dr. Helen Torley Named EY Entrepreneur Of The Year 2018 San Diego PR Newswire
Jun-01-18 08:30AM  Halozyme Identifies Plasma Biomarkers As Potential Predictors Of Survival In Pancreatic Cancer PR Newswire
May-29-18 04:15PM  Halozyme Therapeutics To Participate In Upcoming Healthcare Conferences PR Newswire
May-24-18 03:00AM  Halozyme Therapeutics Clears Technical Benchmark, Hitting 80-Plus RS Rating Investor's Business Daily
May-15-18 08:00AM  Today's Research Reports on Trending Tickers: OPKO Health and Halozyme Therapeutics ACCESSWIRE
May-11-18 03:46AM  Edited Transcript of HALO earnings conference call or presentation 10-May-18 8:30pm GMT Thomson Reuters StreetEvents -5.73%
May-10-18 04:44PM  Halozyme Therapeutics: 1Q Earnings Snapshot Associated Press
04:05PM  Halozyme Reports First Quarter 2018 Results PR Newswire
Apr-10-18 08:00AM  Halozyme To Host First Quarter 2018 Financial Results Conference Call PR Newswire
Mar-22-18 05:46PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Halozyme Therapeutics, Inc. Business Wire
04:05PM  Halozyme Announces Nomination Of Directors For Reelection At 2018 Stockholder Meeting PR Newswire
Mar-14-18 04:37PM  Halozyme To Present Data From Six Nonclinical Studies At American Association Of Cancer Research Annual Conference PR Newswire
Mar-01-18 04:26PM  Edited Transcript of HALO earnings conference call or presentation 20-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
Feb-27-18 08:00AM  Halozyme Therapeutics To Present At Upcoming Healthcare Conference PR Newswire
Feb-23-18 07:45AM  New Research: Key Drivers of Growth for Trinseo S.A, Camden Property Trust, Lions Gate Entertainment, Aramark, J.M. Smucker, and Halozyme Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Feb-22-18 08:10AM  Todays Research Reports on Stocks to Watch: Halozyme Therapeutics and Loxo Oncology ACCESSWIRE
Feb-20-18 04:49PM  Halozyme Therapeutics tops Street 4Q forecasts Associated Press
04:05PM  Halozyme Reports Fourth Quarter And Full-Year 2017 Results PR Newswire
12:00PM  Halozyme Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-15-18 09:00AM  Options Traders Expect Huge Moves in Halozyme Therapeutics (HALO) Stock Zacks
Feb-09-18 10:22AM  Halozyme Therapeutics Inc (NASDAQ:HALO): Should The Recent Earnings Drop Worry You? Simply Wall St.
Feb-05-18 05:43PM  First Eagle Reduces Halozyme Therapeutics Stake GuruFocus.com
Feb-02-18 07:14PM  Cramer's lightning round: Shopify's doing well, but you s... CNBC Videos
Jan-29-18 05:39PM  First Eagle Fund of America 4th Quarter Commentary GuruFocus.com
Jan-25-18 08:10AM  Todays Research Reports on Stocks to Watch: Cerus Corporation and Halozyme Therapeutics ACCESSWIRE
Jan-22-18 08:00AM  Halozyme To Host Fourth Quarter And Full-Year 2017 Financial Results Conference Call PR Newswire +5.39%
Jan-19-18 02:46PM  Glancy Prongay & Murray LLP Commences Investigation on Behalf of Halozyme Therapeutics, Inc. Investors (HALO) Business Wire
Jan-17-18 02:50PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Halozyme Therapeutics, Inc. (HALO) PR Newswire -8.92%
01:48PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Halozyme Therapeutics, Inc. - HALO PR Newswire
12:05PM  This News Explains Halozyme Therapeutics' Double-Digit Drop Today Motley Fool
Jan-11-18 03:00AM  Stocks To Watch: Halozyme Therapeutics Sees RS Rating Rise To 92 Investor's Business Daily
Jan-09-18 06:30PM  Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018 PR Newswire
Jan-02-18 08:07AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Jan-01-18 09:18AM  Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018 Capital Cube
Dec-27-17 08:00AM  Halozyme Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-26-17 10:30AM  3 Top Stocks Wall Street Is Overlooking Motley Fool
Dec-19-17 01:11PM  ETFs with exposure to Halozyme Therapeutics, Inc. : December 19, 2017 Capital Cube
Dec-18-17 07:14PM  Cramer's lightning round: Roku's one of the most amazing ... CNBC Videos
Dec-15-17 09:12AM  The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals Zacks
08:55AM  Why Halozyme Therapeutics (HALO) Could Be Positioned for a Surge Zacks
Dec-11-17 09:02AM  Analyst Recommendations for Alexion in December 2017 Market Realist
08:35AM  Options Traders Expect Huge Moves in Halozyme Therapeutics (HALO) Stock Zacks
Dec-08-17 08:10AM  Todays Research Reports on Stocks to Watch: Halozyme Therapeutics and Xoma Corporation ACCESSWIRE
Dec-07-17 09:26AM  Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers TheStreet.com
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company's pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and cholangiocarcinoma and gall bladder cancer. In addition, the company develops PEGylated adenosine deaminase 2, an immune checkpoint inhibitor that targets adenosine. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; and Alexion Pharma Holding. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KIRK RANDAL J10% OwnerAug 28Sale18.02432,2497,789,1271,897,610Aug 28 05:25 PM
KIRK RANDAL J10% OwnerAug 27Sale18.22109,3771,992,8492,154,470Aug 28 05:25 PM
KIRK RANDAL J10% OwnerAug 24Sale18.20103,3721,881,3702,219,466Aug 28 05:25 PM
KIRK RANDAL J10% OwnerAug 23Sale18.48251,3354,644,6712,280,894Aug 23 04:33 PM
KIRK RANDAL J10% OwnerAug 22Sale17.49781,88113,675,0992,430,247Aug 23 04:33 PM
KIRK RANDAL J10% OwnerAug 21Sale17.15161,2462,765,3692,894,871Aug 23 04:33 PM
KIRK RANDAL J10% OwnerAug 16Sale17.2495,3631,644,0582,985,054Aug 16 05:16 PM
KIRK RANDAL J10% OwnerAug 15Sale17.1591,5411,569,9283,041,722Aug 16 05:16 PM
KIRK RANDAL J10% OwnerAug 14Sale17.36303,1685,262,9963,096,119Aug 16 05:16 PM
KIRK RANDAL J10% OwnerAug 10Sale17.08202,9593,466,5403,276,273Aug 10 05:00 PM
KIRK RANDAL J10% OwnerAug 09Sale17.48223,1273,900,2603,396,879Aug 10 05:00 PM
KIRK RANDAL J10% OwnerAug 08Sale17.52146,7182,570,4993,529,470Aug 10 05:00 PM
KIRK RANDAL J10% OwnerJul 27Sale16.9048,927826,8663,616,655Jul 27 04:35 PM
KIRK RANDAL J10% OwnerJul 26Sale17.30150,0002,595,0003,645,729Jul 27 04:35 PM
KIRK RANDAL J10% OwnerJul 25Sale17.32103,9001,799,5483,734,865Jul 27 04:35 PM
KIRK RANDAL J10% OwnerJun 29Sale16.97122,4312,077,6543,796,606Jun 29 09:55 PM
KIRK RANDAL J10% OwnerJun 28Sale16.99128,3852,181,2613,869,359Jun 29 09:55 PM
KIRK RANDAL J10% OwnerJun 27Sale17.3453,505927,7773,945,650Jun 29 09:55 PM
Stelzer LaurieSVP, Chief Financial OfficerJun 15Option Exercise0.006,875054,385Jun 18 04:23 PM
Chondros DimitriosSVP, Chief Medical OfficerJun 01Option Exercise0.002,043036,119Jun 05 04:06 PM
LEONHARDT HARRY JSVP, GC and CCOApr 13Option Exercise0.006,875041,935Apr 13 07:15 PM
LEONHARDT HARRY JSVP, GC and CCOFeb 22Option Exercise0.0011,392038,999Feb 23 05:14 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 22Option Exercise0.0011,392051,449Feb 23 05:13 PM
Torley HelenPresident and CEOFeb 22Option Exercise0.0039,3540348,997Feb 23 05:09 PM
Torley HelenPresident and CEOFeb 06Option Exercise0.0031,2500325,136Feb 06 07:43 PM
LEONHARDT HARRY JSVP, GC and CCOFeb 03Option Exercise0.0015,413033,212Feb 05 04:27 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 03Option Exercise0.0023,120048,322Feb 05 04:25 PM
Torley HelenPresident and CEOFeb 03Option Exercise0.0055,4870317,997Feb 05 04:22 PM
Torley HelenPresident and CEOJan 06Option Exercise0.0030,0000274,159Jan 09 06:35 PM